Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BETonMACE: Apabetalone in High-Risk T2DM with CAD
NCT02586155Phase 3Completed
- Sponsor
- Resverlogix Corp.
- Start
- Nov 2015
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of apabetalone in coronary artery disease (CAD), sponsored by Resverlogix Corp.. Started Nov 2015; status: completed.
02
Drugs
apabetalone
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT02586155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586155.